Patient characteristics of 130 relapse and refractory multiple myeloma... | Download Scientific Diagram
Cardiovascular Complications of Novel Multiple Myeloma Treatments | Circulation
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Clinical Trials in R/R Multiple Myeloma
Carfilzomib in multiple myeloma | PPT
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group - The Lancet Oncology
Healthcare reality of the treatment of the high-risk multiple myeloma in Spain | Medicina Clínica (English Edition)
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost | International Journal of Hematology
Cells | Free Full-Text | Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
Takeda Oncology on X: "Multiple #myeloma may be the most common, but DYK there are several other forms of myeloma? Take action, learn more https://t.co/aDKofURa4c https://t.co/aFizSxMTn0" / X
Dr. Reddy's Laboratories Ltd. - Multiple myeloma is a cancer of plasma cells that generally affects people in the age group of 52-61 years and early diagnosis is possible with routine blood
Biomedicines | Free Full-Text | Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
How I treat high-risk multiple myeloma - ScienceDirect
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS) | Annals of Hematology
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice